251 related articles for article (PubMed ID: 18037229)
1. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.
Tian D; Das SG; Doshi JM; Peng J; Lin J; Xing C
Cancer Lett; 2008 Feb; 259(2):198-208. PubMed ID: 18037229
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
3. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
4. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis.
Doshi JM; Tian D; Xing C
Mol Pharm; 2007; 4(6):919-28. PubMed ID: 17874842
[TBL] [Abstract][Full Text] [Related]
5. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
[TBL] [Abstract][Full Text] [Related]
6. BH3 mimetic-elicited Ca
Ferdek PE; Jakubowska MA; Nicolaou P; Gerasimenko JV; Gerasimenko OV; Petersen OH
Cell Death Dis; 2017 Mar; 8(3):e2640. PubMed ID: 28252652
[TBL] [Abstract][Full Text] [Related]
7. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2.
Sinicrope FA; Penington RC
Mol Cancer Ther; 2005 Oct; 4(10):1475-83. PubMed ID: 16227396
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
9. Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells.
Jin CY; Park C; Lee JH; Chung KT; Kwon TK; Kim GY; Choi BT; Choi YH
Toxicol In Vitro; 2009 Mar; 23(2):259-65. PubMed ID: 19124070
[TBL] [Abstract][Full Text] [Related]
10. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
11. Effect of HA14-1 on apoptosis-regulating proteins in HeLa cells.
Rehman K; Tariq M; Akash MS; Gillani Z; Qazi MH
Chem Biol Drug Des; 2014 Mar; 83(3):317-23. PubMed ID: 24118733
[TBL] [Abstract][Full Text] [Related]
12. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
13. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
[TBL] [Abstract][Full Text] [Related]
14. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.
Hermanson D; Addo SN; Bajer AA; Marchant JS; Das SG; Srinivasan B; Al-Mousa F; Michelangeli F; Thomas DD; Lebien TW; Xing C
Mol Pharmacol; 2009 Sep; 76(3):667-78. PubMed ID: 19561125
[TBL] [Abstract][Full Text] [Related]
15. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
16. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Wong FY; Liem N; Xie C; Yan FL; Wong WC; Wang L; Yong WP
PLoS One; 2012; 7(12):e50786. PubMed ID: 23226540
[TBL] [Abstract][Full Text] [Related]
18. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor.
Wu X; Zhang LS; Toombs J; Kuo YC; Piazza JT; Tuladhar R; Barrett Q; Fan CW; Zhang X; Walensky LD; Kool M; Cheng SY; Brekken R; Opferman JT; Green DR; Moldoveanu T; Lum L
Nat Cell Biol; 2017 Oct; 19(10):1226-1236. PubMed ID: 28945232
[TBL] [Abstract][Full Text] [Related]
19. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
Tumilasci VF; Olière S; Nguyên TL; Shamy A; Bell J; Hiscott J
J Virol; 2008 Sep; 82(17):8487-99. PubMed ID: 18579592
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
